A descriptive analysis of real-world treatment patterns of innovator (Remicade&lt;sup&gt;&amp;reg;&lt;/sup&gt;) and biosimilar infliximab in an infliximab-na&amp;iuml;ve Turkish population

Yazıcı, Yusuf; Xie, Lin; Ogbomo, A; Ellis, Lorie; Goyal, Kavitha; Teeple, Amanda; Mutlu, Ece; Şimşek, İsmail

doi:10.2147/btt.s172241

Cited by 6 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the effect of afucosylation variations in sarcoidosis has not been extensively studied. In the study by Yazici et al [ 34 ] performed in Turkey, 72% of patients retransitioned. According to the authors, the incentives for the use of biosimilars are minimal in Turkey, since both originators and biosimilars are fully reimbursed [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

“…In the study by Yazici et al [ 34 ] performed in Turkey, 72% of patients retransitioned. According to the authors, the incentives for the use of biosimilars are minimal in Turkey, since both originators and biosimilars are fully reimbursed [ 34 ]. However, as other countries also reimburse both originators and biosimilars, this cannot fully explain their large cumulative incidence of retransitioning.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Background Transitioning patients from an originator to a corresponding biosimilar has been extensively studied in both randomized controlled trials and observational studies. Although transitioning is considered well-tolerated, with no negative impacts on efficacy and/or safety, 2.6-25.8% of patients restart treatment with the originator (retransitioning). Retransitioning to the originator can be considered an indication of biosimilar treatment failure or dissatisfaction with biosimilar treatment. Increasing our knowledge of patients who retransition might help to reduce the number of patients retransitioning. Objective Our objective was to estimate the cumulative incidence of patients who retransitioned from a tumor necrosis factor (TNF)-α inhibitor biosimilar to originator and to explore potential patient, disease, and treatment and implementation strategy factors associated with retransitioning. Method We conducted a systematic literature search in the PubMed, EMBASE, and Cochrane Central Register of controlled trials databases until March 2021. Studies on TNFα inhibitors, biosimilar transitioning, and retransitioning were included. Transitioning was defined as switching from an originator to a biosimilar, and retransitioning was defined as switching from an originator to a biosimilar and back to the originator. Characteristics of the studies were descriptively analyzed. Studies were weighted by the number of patients transitioning, and the primary outcome was the median cumulative incidence of retransitioning. For each of the factors related to patient, disease, and treatment and implementation strategy, studies were stratified according to the categories of that factor. The weighted medians and interquartile ranges (IQRs) of the cumulative incidence of retransitioning in these studies were calculated and compared to explore whether a potential association existed between these factors and the cumulative incidence of retransitioning. Results Of 994 screened publications, 37 were included. The weighted median cumulative incidence of retransitioning was 7.6% (IQR 6.8-17.2). Studies that included only patients with inflammatory bowel disease (6.6 vs. 15.1-17.7% for other indications), included only patients with stable disease (7.0 vs. 13.7% for including all patients), and did not offer retransitioning at the introduction of the biosimilar (7.0 vs. 11.1% for studies that offered retransitioning) reported less retransitioning. In addition, the incidence of retransitioning was lower when extra laboratory monitoring was part of the implementation strategy (1.6 vs. 6.1%) and when gainsharing (patients' healthcare directly benefits from financial savings from transitioning) (1.4 vs. 7.2% for studies without gainsharing) was applied. Conclusions In studies on transitioning patients from TNFα originator to biosimilar, 8% of patients retransitioned. Retransitioning appeared to be lower in studies that included only patients with stable disease and in studies that did not offer patients the option of retransitioning at...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

show abstract

Using real‐world data to evaluate biosimilar switching

Dutcher

Eworuke

Blum

et al. 2019

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness

Dutcher

Fazio‐Eynullayeva

Eworuke

et al. 2019

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

Purpose: To describe utilization of filgrastim and infliximab, the first two products with biosimilars approved in the United States. Methods: We identified use of filgrastim (reference, tbo-filgrastim, and filgrastimsndz) and infliximab (reference, infliximab-dyyb, and infliximab-abda) in the Sentinel Distributed Database using Healthcare Common Procedure Coding System (HCPCS) codes and National Drug Codes (NDCs) from January 2015 to August 2018. We calculated the proportion of use by code type and assessed uptake over time. We compared baseline patient characteristics and treatment indications. Among patients with >1 exposure episode, we characterized gaps between episodes. Results: Use was identified primarily via HCPCS codes (filgrastim: 86.4%-97.7%; infliximab: 87.8%-100%) although some was identified via NDCs (filgrastim: 2.2%-13.5%; infliximab: <0.1%-6.5%). Filgrastim reference product use declined from 89.4% in January 2015 to 30.3% in June 2018, with corresponding increases in filgrastim-sndz (0% to 49.3%) and tbo-filgrastim (10.6% to 20.4%). Infliximab biosimilar uptake was low (9.7% in June 2018). We identified 94 846 filgrastim reference product, 27 143 tbo-filgrastim, and 38 264 filgrastim-sndz users. For infliximab, we identified 125 412 reference product, 1034 infliximab-dyyb, 49 infliximab-abda, and 4855 undetermined biosimilar users. Patients receiving filgrastim products were largely similar, but differences in age, sex, and indication were observed across infliximab product users. The median exposure episode gap ranged from 1 to 3 days for filgrastim and 48 to 50 days for infliximab. Conclusion: Use of biosimilar filgrastim has increased in the United States, but infliximab biosimilar use remains low. Data on identification of biosimilars in claims data and observed gaps between exposure episodes can be used to support drug safety studies of biosimilars.

show abstract

A descriptive analysis of real-world treatment patterns of innovator (Remicade<sup>®</sup>) and biosimilar infliximab in an infliximab-naïve Turkish population

Cited by 6 publications

References 22 publications

Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review

Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review

Using real‐world data to evaluate biosimilar switching

Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness

Contact Info

Product

Resources

About